Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF582 vs Lucentis in Neovascular AMD
NCT02121353Phase 2Completed
- Sponsor
- Pfenex Inc.
- Start
- Nov 2013
- Primary completion
- Jan 2016
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab biosimilar PF582 in neovascular age-related macular degeneration (NVAMD), sponsored by Pfenex Inc.. Started Nov 2013; status: completed.
02
Drugs
ranibizumab biosimilar PF582
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02121353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121353.